◆ 会议时间：2024年5月15日至17日
◆ 会议地点：瑞士 巴塞尔

◆ 会议简介：

2024年第10届欧洲卒中组织大会(ESOC)将于2024年5月15日至17日在瑞士巴塞尔举行，会议由欧洲卒中组织主办。ESOC是欧洲讨论和传播有关卒中护理最新进展的首要论坛，已成为世界上最重要的发布重大试验数据的平台。ESOC将促进欧洲和国际卒中专家间的学习、讨论和交流，同时为与会者提供了一个了解卒中管理、治疗和预防的最新临床试验和研究成果的平台，预计来自全球100多个国家的4000余名专业人士参会(2023年有来自96个国家/地区的4,172的代表参会)。

欧洲卒中组织(ESO)成立于2007年，是一个由脑卒中研究人员、医师、国家和区域卒中学会等组成的泛欧洲非政府组织，现在世界各地拥有超过7000名成员。ESO的宗旨是通过向医护专业人员和普通大众提供医学教育来改善卒中护理；制定和推广公共政策，减少卒中死亡人数，改善卒中患者的护理和生活质量；促进对卒中各个方面的认识、管理、教学和研究；发展和推广专业与公共宣教育；通过国家/区域组织发展、促进和协调国际教学计划等等。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）

ESOC 2024 - 10th Annual European Stroke Organisation Conference
Date: 15–17 May 2024
Venue: Congress Center and Messe Basel (Basel, Switzerland)

ESOC is Europe’s leading forum for advances in research and clinical care of patients with cerebrovascular diseases. ESOC 2023 will live up to its expectation, and present to you a packed, high quality scientific programme including major clinical trials, state-of-the-art seminars, educational workshops, scientific communications of the latest research, and debates about current controversies.

摘要征文投稿：

2 NOVEMBER 2023
Opening abstract submissions

15 JANUARY 2024, 23:59 CET
Abstract submission deadline

MID-MARCH 2024
Abstract results announced via e-mail

点此提交摘要>>>Submit Abstract>>>

Review the submission guidelines

Guidelines for the preparation of abstracts

Please carefully read the below Guidelines for the preparation of your abstract.

1. Online submission only – Abstracts sent by fax or email will not be accepted.
2. Authors should indicate their presentation type preference:
   • Poster presentation only
   • Oral or poster presentation
     Note: “Poster presentation only” implies that your abstract will be considered for poster presentation only.
3. One person may serve as presenting author on up to 5 abstracts.
4. The Scientific Programme Committee reserves the right to decide on the final allocation and presentation method.
5. All abstracts should be submitted and presented in clear UK English with accurate grammar and spelling of a quality suitable for publication. If you need help, arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
6. You may enter up to 10 authors in the authors list including the presenter.
   If you have more than 10 authors, you can use the “On behalf of” field to enter the name of an investigating team/study group.
7. The presenting author of an accepted abstract must register and attend the congress to ensure the publication of abstracts.
8. Submission of an abstract acknowledges your acceptance for the abstract to be published in the official conference publications.
9. The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
10. Abstracts that have been previously presented at another international meeting cannot be considered for a plenary session.
11. Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
12. Abstract text – limited to 250 words including acknowledgements. Note that word count is affected when tables are included. Tables (3 max) may be added at the end of the template (word file).
13. Abstracts should clearly state:
    Background and aims
    Methods
    Results
    Conclusions
14. Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
15. Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
16. Images – The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format. Images (3 max) may be added at the end of the template (word file).
17. Submissions may not contain patient names, hospital ID numbers or other identifying information.
18. Disclosure of Conflicts of Interest: Please disclose any conflict of interests the authors might have and indicate in the custom queries during the submission process.
19. Important:
    As the grading and selection process is blind, the title and body text must not contain identifying features, i.e. information such as:
    • Names (authors or others)
    • Names of the institutes (hospitals, medical schools, clinics…)
    • Cities
20. Make sure to state your correct e-mail address. After having submitted your abstract, you will receive a confirmation by e-mail with the following information:
    • reference number of your abstract (for correspondence and questions that might arise)
    • title of your submitted abstract
    If you do not receive a confirmation by e-mail, please contact ESOC.abstracts@congrex.com
21. Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal log-in. This will shorten the submission procedure.
    Corrections to abstracts can only be made up to the deadline of 15 January 2024, 23:59h CET.

Notification
Each abstract will be reviewed and rated by at least 4 external blinded experts and final selection will be made by the Scientific Programme Committee. Notification of acceptance or rejection of submitted abstracts will be sent to the corresponding authors via email by mid-March 2024. Full instructions concerning preparation and presentation will be included and will be made available on the conference website.

Publication
ESOC 2024 has an embargo policy on all abstracts submitted to the conference. The embargo will be lifted on 15 May 2024. All accepted abstracts will be published in the peer-reviewed journal.

ESOC2024 注册费：

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。